Literature DB >> 15685618

Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma.

Toshifumi Wakai1, Yoshio Shirai, Tetsuya Moroda, Naoyuki Yokoyama, Katsuyoshi Hatakeyama.   

Abstract

BACKGROUND: The current study was performed to clarify whether the presence of residual carcinoma in situ at ductal resection margins differs prognostically from residual invasive ductal lesions in patients undergoing surgical resection for extrahepatic cholangiocarcinoma.
METHODS: A retrospective analysis of 84 patients with extrahepatic cholangiocarcinoma who underwent surgical resection was conducted. The ductal resection margin status was classified as negative (n = 64 patients), positive with carcinoma in situ (n = 11 patients), or positive with invasive carcinoma (n = 9 patients). The median follow-up period was 105 months.
RESULTS: Ductal margin status was found to be a strong independent prognostic factor by both univariate (P = 0.0002) and multivariate (P = 0.0039) analyses. The outcome after surgical resection was comparable between patients with negative ductal margins (median survival time of 45 months; cumulative 10-year survival rate of 40%) and those with positive ductal margins with carcinoma in situ (median survival time of 99 months; cumulative 10-year survival rate of 23%; P = 0.4742). In patients with positive ductal margins, the outcome was found to be significantly better in patients with residual carcinoma in situ than in those with residual invasive carcinoma (median survival time of 21 months; cumulative 5-year survival rate of 0%; P = 0.0003). Of 11 patients with residual carcinoma in situ, 4 died of tumor recurrence and the initial site of the disease recurrence was local. All 9 patients with residual invasive carcinoma died of disease recurrence (local recurrence with or without distant metastases) within 40 months after surgical resection.
CONCLUSIONS: After surgical resection for extrahepatic cholangiocarcinoma, invasive carcinoma at ductal resection margins appears to have a strong adverse effect on patient survival, whereas residual carcinoma in situ does not.

Entities:  

Mesh:

Year:  2005        PMID: 15685618     DOI: 10.1002/cncr.20906

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  66 in total

1.  A new variant of bile duct duplication with coexistence of distal cholangiocarcinoma.

Authors:  Ilkay Kosar; Hilmi Ataseven; Ozlem Yönem; Erol Cakmak; Ozdemir Ozer; Hatice Ozer; Omer Topçu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-10       Impact factor: 46.802

2.  Isolated caudate lobectomy with pancreatoduodenectomy for a bile duct cancer.

Authors:  Tsuyoshi Sano; Yasuhiro Shimizu; Yoshiki Senda; Koji Komori; Seiji Ito; Tetsuya Abe; Taira Kinoshita; Yuji Nimura
Journal:  Langenbecks Arch Surg       Date:  2013-09-13       Impact factor: 3.445

3.  Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma.

Authors:  Jun Sakata; Yoshio Shirai; Toshifumi Wakai; Tatsuya Nomura; Eiko Sakata; Katsuyoshi Hatakeyama
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

Review 4.  Intraoperative assessment of the Whipple resection specimen.

Authors:  Mahmoud A Khalifa
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

5.  Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma.

Authors:  Ryoko Sasaki; Yuichiro Takeda; Osamu Funato; Hiroyuki Nitta; Hidenobu Kawamura; Noriyuki Uesugi; Tamotsu Sugai; Go Wakabayashi; Nobuhiro Ohkohchi
Journal:  World J Surg       Date:  2007-07-25       Impact factor: 3.352

Review 6.  [Frozen section diagnostics in visceral surgery. Liver, bile ducts and pancreas].

Authors:  C Mogler; C Flechtenmacher; P Schirmacher; F Bergmann
Journal:  Pathologe       Date:  2012-09       Impact factor: 1.011

7.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

8.  Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tomoharu Yoshizumi; Shinichi Aishima; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

9.  Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment.

Authors:  Satoshi Kondo; Tadahiro Takada; Masaru Miyazaki; Shuichi Miyakawa; Kazuhiro Tsukada; Masato Nagino; Junji Furuse; Hiroya Saito; Toshio Tsuyuguchi; Masakazu Yamamoto; Masato Kayahara; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Satoshi Hirano; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16

10.  Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.

Authors:  Kyu-Hyoung Lim; Do-Youn Oh; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Sung Whan Ha; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2009-09-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.